Valve in Valve Presents Better Evolution than re-SARV

Courtesy of Dr. Carlos Fava.

Surgical aortic valve replacement with bioprosthesis has proved its benefits, but it fails after 10 to 15 years. 

valve_in_valve-compressor

Transcatheter aortic valve replacement has been shown valid, especially in high risk patients, but we still have little information and no “head to head” studies to know what is best in this group that keeps growing over the years. 

A retrospective analyzis of the National Readmissions Database (NRD) from 2012 to 2016 was carried out, including 6815 procedures, 3443 (50.5%) receiving V-in-V TAVI and 3372 re-SAVR.

The V-in-V TAVR group had older patients, with prior CABG, kidney function deterioration and cardiac failure. 

At 30 days, this population had lower mortality (2.8% vs. 5.0%; OR 0.55, 95% CI 0.33 – 1.91), morbidity (66.4% vs. 79%; OR 0.52, 95% CI 0.41 – 0.66) and major bleeding (35.8% vs. 49.9%; OR 0.56, 95% CI 0.44 – 0.71). In addition, it presented shorter hospital stay (7 vs. 9 days, on average 2 days, 95% CI 1.4 – 2.6) and higher home discharge (45.9% vs. 34.2%; OR 1.57, 95% CI 1.28 – 1.93).


Read also: EuroPCR 2020 | Aortic Valve in Valve in the Long Term.


There were no differences in stroke, kidney failure, need for pacemaker, A-V block or cost between procedures. Likewise, there were no differences in rehospitalization need within 30 days. 

On multivariable analyzis, the re-SAVR group was associated with higher mortality and morbidity and 30’ days.

When comparing groups, propensity score matching left 2181 pairs. 


Read also: Is V-in-V the Treatment of Choice in Cases of Failed Biological Prosthesis?


At 30 day followup, V-in-V TAVR was associated to lower mortality (OR 0.41, 95% CI 0.23–0.74), lower morbidity (OR 0.53, 95% CI 0.43–0.72), lower major bleeding (OR 0.66, 95% CI 0.51–0.85), shorter hospital stay (on average two days 95% CI 1.3–2.7) and higher discharge (OR 2.11, 95% CI 1.61–2.78) compared against re-SAVR.

Patients undergoing re-SAVR had 59% more mortality, 63% morbidity and 71% major bleeding. Patients in the V-in-V TAVR group showed 3.9 more chances of home discharge compared against re-SAVR patients.

Conclusion

In this study of high-risk population with bioprosthetic aortic valve failure, V-in-V TAVR seems to have an advantage over re-SAVR at 30 days in terms of mortality, morbidity, and major bleeding.

Further study is necessary in low, intermediate, and high-risk patients to look into long term effectiveness. 

Gentileza del Dr. Carlos Fava.

Original Title: Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes.

Reference: Sameer A. Hirji, et al. European Heart Journal (2020) 0, 1–9. doi:10.1093/eurheartj/ehaa252.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...